Free Trial

Veracyte (VCYT) Competitors

Veracyte logo
$43.05 -0.55 (-1.26%)
Closing price 04:00 PM Eastern
Extended Trading
$43.06 +0.02 (+0.03%)
As of 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VCYT vs. HIMS, OPCH, GH, RDNT, SHC, BTSG, LFST, CON, PRVA, and SGRY

Should you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Hims & Hers Health (HIMS), Option Care Health (OPCH), Guardant Health (GH), RadNet (RDNT), Sotera Health (SHC), BrightSpring Health Services (BTSG), LifeStance Health Group (LFST), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), and Surgery Partners (SGRY). These companies are all part of the "healthcare" industry.

Veracyte vs.

Veracyte (NASDAQ:VCYT) and Hims & Hers Health (NYSE:HIMS) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Hims & Hers Health has a net margin of 8.19% compared to Veracyte's net margin of -2.18%. Hims & Hers Health's return on equity of 10.97% beat Veracyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Veracyte-2.18% 3.02% 2.80%
Hims & Hers Health 8.19%10.97%8.29%

63.5% of Hims & Hers Health shares are held by institutional investors. 1.3% of Veracyte shares are held by insiders. Comparatively, 17.7% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Veracyte received 401 more outperform votes than Hims & Hers Health when rated by MarketBeat users. Likewise, 73.06% of users gave Veracyte an outperform vote while only 39.05% of users gave Hims & Hers Health an outperform vote.

CompanyUnderperformOutperform
VeracyteOutperform Votes
442
73.06%
Underperform Votes
163
26.94%
Hims & Hers HealthOutperform Votes
41
39.05%
Underperform Votes
64
60.95%

Hims & Hers Health has higher revenue and earnings than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$361.05M9.24-$74.40M-$0.15-287.00
Hims & Hers Health$872M7.43-$23.55M$0.4467.44

In the previous week, Hims & Hers Health had 20 more articles in the media than Veracyte. MarketBeat recorded 25 mentions for Hims & Hers Health and 5 mentions for Veracyte. Veracyte's average media sentiment score of 0.89 beat Hims & Hers Health's score of 0.66 indicating that Veracyte is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veracyte
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Hims & Hers Health
14 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

Veracyte presently has a consensus price target of $41.13, suggesting a potential downside of 4.47%. Hims & Hers Health has a consensus price target of $25.13, suggesting a potential downside of 15.30%. Given Veracyte's stronger consensus rating and higher probable upside, research analysts plainly believe Veracyte is more favorable than Hims & Hers Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veracyte
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
Hims & Hers Health
2 Sell rating(s)
7 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.35

Veracyte has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.

Summary

Hims & Hers Health beats Veracyte on 11 of the 18 factors compared between the two stocks.

Get Veracyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VCYT vs. The Competition

MetricVeracyteMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$3.14B$3.04B$5.36B$9.13B
Dividend YieldN/A16.58%5.37%4.00%
P/E RatioN/A12.0674.7215.64
Price / Sales9.36204.431,287.0785.06
Price / Cash437.23393.5036.3232.99
Price / Book3.055.244.974.69
Net Income-$74.40M-$33.85M$117.89M$224.57M
7 Day Performance4.51%4.49%1.74%1.69%
1 Month Performance6.63%1.06%3.69%5.34%
1 Year Performance65.34%17.87%25.82%21.47%

Veracyte Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VCYT
Veracyte
3.9523 of 5 stars
$43.05
-1.3%
$41.13
-4.5%
+70.8%$3.34B$361.05M-287.00790News Coverage
HIMS
Hims & Hers Health
3.539 of 5 stars
$27.80
-0.5%
$25.13
-9.6%
+257.0%$6.07B$872M63.191,046Insider Trade
OPCH
Option Care Health
4.7608 of 5 stars
$29.16
-0.5%
$29.86
+2.4%
-8.0%$4.96B$4.30B24.507,802Positive News
GH
Guardant Health
3.4099 of 5 stars
$36.66
-1.7%
$40.60
+10.7%
+94.4%$4.53B$563.95M-8.651,779Analyst Forecast
News Coverage
RDNT
RadNet
3.5292 of 5 stars
$59.86
-1.7%
$79.75
+33.2%
+59.3%$4.43B$1.62B-855.0210,288Analyst Forecast
News Coverage
SHC
Sotera Health
2.7372 of 5 stars
$12.98
+2.3%
$16.08
+23.9%
-11.1%$3.68B$1.05B51.923,000
BTSG
BrightSpring Health Services
2.186 of 5 stars
$18.55
+0.4%
$18.65
+0.6%
N/A$3.23B$8.83B-71.3535,000News Coverage
LFST
LifeStance Health Group
1.1646 of 5 stars
$7.99
+0.1%
$8.70
+8.9%
+17.3%$3.06B$1.06B-30.739,325Positive News
CON
Concentra Group Holdings Parent
N/A$21.17
+0.7%
$28.50
+34.6%
N/A$2.70B$1.88B0.0011,000Lockup Expiration
Positive News
Gap Down
PRVA
Privia Health Group
2.6215 of 5 stars
$22.24
+1.8%
$24.88
+11.9%
+9.1%$2.67B$1.66B222.421,102
SGRY
Surgery Partners
1.7847 of 5 stars
$20.19
+1.0%
$36.56
+81.1%
-36.2%$2.57B$2.99B-42.0613,500

Related Companies and Tools


This page (NASDAQ:VCYT) was last updated on 1/22/2025 by MarketBeat.com Staff
From Our Partners